Latent Classes of Lifetime Use of Seven Hallucinogens in the United States

Interest in and use of hallucinogens appears to be growing in the United States, yet less is known about the use of multiple hallucinogens. The aims of this study are to characterize subgroups of lifetime hallucinogen use and to identify sociodemographic correlates of these subgroups. Latent class models were fit using 2021-2022 National Survey on Drug Use and Health (NSDUH) data on a sub-sample of individuals who reported having ever used any hallucinogen (<i>n</i> = 17,977). A four-class model identified the following subgroup classes: <i>Psilocybin</i> (16%), <i>LSD/Psilocybin</i> (46%), <i>Ecstasy</i> (23%), and a fourth class (15%) labeled <i>Multiple substances</i>, with high probabilities of use of psilocybin, LCD, and ecstasy, in addition to moderate probabilities of use of other hallucinogens. In survey-weighted multinomial logistic regression analyses, compared to the <i>Psilocybin</i> class, the adjusted odds of being in the <i>LSD/Psilocybin</i> class increased with age-group level (AORs = 1.5-6.4, 95% CIs:1.3-8.7), and non-White participants had higher odds of being in the <i>Ecstasy</i> class (AORs = 1.7-3.2, 95% CIs:1.1-4.4). As policies regulating and clinical practice with hallucinogens continue to evolve, these patterns of lifetime hallucinogen use demonstrate the overlapping nature of hallucinogen experiences in the U.S. population, which has implications for expanding clinical trial inclusion criteria and establishing a baseline for future trends.